<DOC>
	<DOC>NCT00630500</DOC>
	<brief_summary>A 24-week placebo-controlled parallel group multicentre trial to study the safety and efficacy of memantine in patients with dementia associated with Parkinson's disease and dementia with Lewy bodies. It is hypothesized that memantine will be safe and well tolerated, and more effective than placebo.</brief_summary>
	<brief_title>Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>a diagnosis of Parkinson's disease (Larsen and Dupont, 1994) and dementia (DSM IV(1987; 1994), or Dementia with Lewy bodies (McKeith et al. Neurology 2005) mildtomoderate or moderate dementia (i.e. MMSE 1226, inclusive) the subject has given a written informed consent the subject is able and willing to comply with the study procedures and has a reliable caregiver (i.e. relative or nurse/nurse assistant who sees the patient at least weekly) other brain disease of sufficient severity to cause dementia mental retardation terminal illness with life expectancy shorter than 6 months recent major changes in health status known epilepsy or previous convulsive seizure major depression severe dementia as defined by a Minimental State Examination score of 12 or lower moderate to severe renal impairment (i.e. serum creatinine &gt; 1,5 upper limit normal (ULN) or creatinin clearance &lt; 40ml/minute/1,73 m2 moderate or severe heart disease (NYHA IIIIV) moderate or severe pulmonal disease moderate to severe hepatic impairment (bilirubin or transaminases &gt; 2 times ULN women of childbearing potential (i.e. not postmenopausal and not taking contraceptive the subjects is lactating any laboratory value(s) exceeding the limits of normality if deemed to be clinically relevant by the study physician known allergies to the investigational product</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Dementia associated with Parkinson's disease</keyword>
	<keyword>Dementia with Lewy bodies</keyword>
	<keyword>Memantine</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Parallel group</keyword>
</DOC>